Lansoprazole
- CAS No.
- 103577-45-3
- Chemical Name:
- Lansoprazole
- Synonyms
- PREVACID;Lansoprazol;2-[3-METHYL-4-(2,2,2-TRIFLUORO-ETHOXY)-PYRIDIN-2-YLMETHANESULFINYL]-1H-BENZOIMIDAZOLE;2-(((3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazole;LANSOPRAZOLE, RELATED COMPOUND A2-[[[3-METHYL-4-(2,2,2-TRIFLOUROETHOXY)-2-PYRIDYL]METHYL]SULFONYL]BENZIMIDAZOLE USP STANDARD;Lanz;OGAST;Promp;Ulpax;Zoton
- CBNumber:
- CB6396972
- Molecular Formula:
- C16H14F3N3O2S
- Molecular Weight:
- 369.36
- MOL File:
- 103577-45-3.mol
- MSDS File:
- SDS
- Modify Date:
- 2024/5/20 18:13:44
| Melting point | 178-182°C dec. |
|---|---|
| Boiling point | 555.8±60.0 °C(Predicted) |
| Density | 1.50±0.1 g/cm3(Predicted) |
| storage temp. | 2-8°C |
| solubility | Practically insoluble in water, soluble in anhydrous ethanol, very slightly soluble in acetonitrile. |
| pka | pKa 2.34±0.37 (Occasionally);3.53±0.37 (Occasionally);8.48±0.30 (Occasionally) |
| form | powder |
| color | off-white |
| Merck | 14,5362 |
| BCS Class | 2 |
| InChIKey | MJIHNNLFOKEZEW-UHFFFAOYSA-N |
| CAS DataBase Reference | 103577-45-3(CAS DataBase Reference) |
SAFETY
Risk and Safety Statements
| Symbol(GHS) |  GHS07 |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Signal word | Warning | |||||||||
| Hazard statements | H315-H319-H335 | |||||||||
| Precautionary statements | P261-P264-P271-P280-P302+P352-P305+P351+P338 | |||||||||
| Hazard Codes | Xi | |||||||||
| Risk Statements | 36/37/38 | |||||||||
| Safety Statements | 26-36 | |||||||||
| WGK Germany | 2 | |||||||||
| RTECS | DD9487500 | |||||||||
| HS Code | 29339900 | |||||||||
| Toxicity | dog,LD,oral,> 2gm/kg (2000mg/kg),Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 35, Pg. 387, 1993. | |||||||||
| NFPA 704 |
|
Lansoprazole price More Price(5)
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| Sigma-Aldrich(India) | L8533 | Lansoprazole ≥98% (TLC), powder | 103577-45-3 | 250MG | ₹6841.4 | 2022-06-14 | Buy |
| Sigma-Aldrich(India) | PHR1390 | Lansoprazole Pharmaceutical Secondary Standard; Certified Reference Material | 103577-45-3 | 1G | ₹8270.3 | 2022-06-14 | Buy |
| Sigma-Aldrich(India) | L8533 | Lansoprazole ≥98% (TLC), powder | 103577-45-3 | 1G | ₹18727.25 | 2022-06-14 | Buy |
| TCI Chemicals (India) | L0233 | Lansoprazole | 103577-45-3 | 1G | ₹5400 | 2022-05-26 | Buy |
| TCI Chemicals (India) | L0233 | Lansoprazole | 103577-45-3 | 5G | ₹10800 | 2022-05-26 | Buy |
Lansoprazole Chemical Properties,Uses,Production
Description
Lansoprazole is the second proton pump inhibitor approved as an antiulcer agent for the short term treatment of duodenal ulcer and gastroesophageal reflux disease. Like omeprazole, lansoprazole is reported to be more efficacious than the H2-antagonists in treating peptic ulcer disease.Other potential uses could be in the treatment of Zollinger-Ellison syndrome.
Chemical Properties
White Crystalline Powder
Uses
Used as a gastric proton pump inhibitor. An antiulcerative
General Description
Lansoprazole, 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole(Prevacid), is a white to brownish white, odorless crystallinepowder that is practically insoluble in water.Lansoprazole is a weak base (pyridine N, pKa 3.83.) and aweak acid (benzimidazole N-H, pK 0.62). Like other PPIs,lansoprazole is essentially a prodrug that, in the acidic biophaseof the parietal cell, forms an active metabolite thatirreversibly interacts with the target ATPase of the pump.Lansoprazole must be formulated as encapsulated entericcoatedgranules for oral administration to protect the drugfrom the acidic environment of the stomach.
In the fasting state, about 80% of a dose of lansoprazole(vs. 50% of omeprazole) reaches the systemic circulation,where it is 97% bound to plasma proteins. Thedrug is metabolized in the liver (sulfone and hydroxymetabolites) and excreted in bile and urine, with a plasmahalf-life of about 1.5 hours.
Biological Activity
H + ,K + -ATPase inhibitor (IC 50 = 6.3 μ M) that displays antisecretory and antiulcer activity. Inhibits gastric acid secretion (IC 50 = 0.09 μ M for histamine-induced acid formation) and reduces gastric lesion formation induced by a variety of ulcerative stimuli. Antibacterial against Helicobacter pylori in vitro . Also blocks swelling-dependent chloride channel (ICIswell) in NIH3T3 fibroblasts. More potent than omeprazole (5-Methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole ).
Lansoprazole Preparation Products And Raw materials
Raw materials
1of3
chevron_rightPreparation Products
| Supplier | Tel | Country | ProdList | Advantage | Inquiry |
|---|---|---|---|---|---|
| Jigs Chemical ltd | +919099003427 | Gujarat, India | 239 | 58 | Inquiry |
| SGMR PHARMACEUTICALS PVT LTD | +91-9032001889 +91-9032001889 | Telangana, India | 83 | 58 | Inquiry |
| ANWITA APIS | +919000311012 | Hyderabad, India | 198 | 58 | Inquiry |
| Micro Orgo Chem | +91-91-022-24969510 +91-9082984052 | Mumbai, India | 66 | 58 | Inquiry |
| J S LABS | +91-7330612784 +91-7330612784 | Tamil Nadu, India | 160 | 58 | Inquiry |
| HEMA LABORATORIES | +919700665792 | Karnataka, India | 15 | 58 | Inquiry |
| Vivimed Labs Ltd | +914066086608 | Telangana, India | 61 | 58 | Inquiry |
| Enal Drugs Pvt Ltd | +914044753636 | Telangana, India | 35 | 58 | Inquiry |
| Honour Lab Limited | +919845977466 | Telangana, India | 164 | 58 | Inquiry |
| Lee Pharma Ltd | +91-9849085929 +91-9849085929 | Hyderabad, India | 42 | 58 | Inquiry |
| Supplier | Advantage |
|---|---|
| Jigs Chemical ltd | 58 |
| SGMR PHARMACEUTICALS PVT LTD | 58 |
| ANWITA APIS | 58 |
| Micro Orgo Chem | 58 |
| J S LABS | 58 |
| HEMA LABORATORIES | 58 |
| Vivimed Labs Ltd | 58 |
| Enal Drugs Pvt Ltd | 58 |
| Honour Lab Limited | 58 |
| Lee Pharma Ltd | 58 |
103577-45-3(Lansoprazole)Related Search:
1of4
chevron_right